About Multiprofile Hosp. for Active Treatment;National Cardiology Hosp.
Националната кардиологична болница е многопрофилна болница за активно лечение в София. Тя е университетска болница – част от структурата на Софийския медицински университет. МБАЛ „НКБ“ е единствената болница в България с отделения за детска кардиология и детска кардиохирургия.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
4
UroGen Pharma Ltd.
2
Clinical Trials at Multiprofile Hosp. for Active Treatment;National Cardiology Hosp.
During the past decade, Multiprofile Hosp. for Active Treatment;National Cardiology Hosp. conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on
average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
2011-03-02
2022-12-31
Completed
735
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
2017-03-24
2024-08-15
Active, not recruiting
1,239
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
2018-11-12
2025-07-26
Active, not recruiting
1,700
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
2018-07-12
2025-08-26
Recruiting
1,500
A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
2021-02-19
2023-03-17
Terminated
282
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
2022-03-01
2028-02-01
Active, not recruiting
220
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Multiprofile Hosp. for Active Treatment;National Cardiology Hosp.
According to Clinical.Site data, the most researched conditions in "Multiprofile Hosp. for Active Treatment;National Cardiology Hosp." are
"Bladder Cancer" (2 trials), "Multiple Sclerosis" (2 trials), "Urothelial Carcinoma" (2 trials), "Urothelial Carcinoma Bladder" (2 trials) and "Multiple Sclerosis, Primary Progressive" (1 trials). Many other conditions were trialed in "Multiprofile Hosp. for Active Treatment;National Cardiology Hosp." in a lesser frequency.
Clinical Trials Intervention Types at Multiprofile Hosp. for Active Treatment;National Cardiology Hosp.
Most popular intervention types in "Multiprofile Hosp. for Active Treatment;National Cardiology Hosp." are "Drug" (6 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.
The name of intervention was led by "Ocrelizumab" (4 trials), "UGN-102" (2 trials), "Placebo" (1 trials) and "TURBT" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Multiprofile Hosp. for Active Treatment;National Cardiology Hosp.
The vast majority of trials in "Multiprofile Hosp. for Active Treatment;National Cardiology Hosp." are
6 trials for "All" genders.
Clinical Trials Status at Multiprofile Hosp. for Active Treatment;National Cardiology Hosp.
Currently, there are NaN active trials in "Multiprofile Hosp. for Active Treatment;National Cardiology Hosp.".
undefined are not yet recruiting,
1 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in Multiprofile Hosp. for Active Treatment;National Cardiology Hosp.,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Multiprofile Hosp. for Active Treatment;National Cardiology Hosp., 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 5 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".